A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients

(2012) Imke H. Bartelink et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults

(2012) Lena E. Friberg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

(2012) Sravanthi Cheeti et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology

(2012) A Rostami-Hodjegan   CLINICAL PHARMACOLOGY & THERAPEUTICS

Therapeutic Monitoring of Voriconazole in Children Less Than Three Years of Age

(2012) Elizabeth H. Doby et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use

(2011) Bharat Damle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy Adults

(2011) Timothy A. Driscoll et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects

(2011) D E Salazar et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers

(2011) SeungHwan Lee et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Human Tissue Distribution of Voriconazole

(2010) Stefan Weiler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children

(2010) T. J. Walsh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Modelling and PBPK Simulation in Drug Discovery

(2009) Hannah M. Jones et al.   AAPS Journal

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

(2009) Ina Scholz et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3

(2009) S. B. Yanni et al.   DRUG METABOLISM AND DISPOSITION

Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study

(2009) Pravin R. Jadhav et al.   PHARMACEUTICAL STATISTICS

Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies

(2008) M. O. Karlsson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes

(2008) S. B. Yanni et al.   DRUG METABOLISM AND DISPOSITION

Pediatric Antihypertensive Trial Failures

(2008) Daniel K. Benjamin et al.   HYPERTENSION

CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

(2008) Johanna Weiss et al.   JOURNAL OF CLINICAL PHARMACOLOGY